Table 3.
BALF lymphocyte subsets assessed by flow cytometry of mitogen stimulated cells.
| Mitogen stimulated cells | Sarcoidosis (N = 23) |
Other DPLDs (N = 11) |
Healthy controls (N = 15) |
P* |
|---|---|---|---|---|
| Th1 (IFN-γ +, % of CD4+ T cells) | 75.5 (62.6–79.4) | 62.1 (46.7–75.0) | 65.7 (41.5–69.6) | n.s |
|
| ||||
| Th17 cells (% of CD4+ T cells) | 2.5 (1.4–4.5) | 3.0 (1.8–6.6) | 4.5 (3.2–8.5) | 0.01 |
|
| ||||
| IFN-γ + Th17 (% of Th17) | 72.4 (57.1–83.8) | 65.5 (39.9–85.9) | 31.0 (22.3–49.6) | 0.0005 |
|
| ||||
| IFN-γ + CD8+ T cells (% of CD8+) | 83.4 (69.3–87.9) | 83.1 (76.4–94.3) | 85.5 (77.5–89.9) | n.s |
|
| ||||
| IL17+ CD8+ T cells (% of CD8+) | 0.8 (0.5–2.4) | 0.5 (0.3–1.4) | 1.1 (0.9–1.6) | n.s |
Data are shown as median (IQR). *P values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney U test conducted if significant differences were found with Kruskal-Wallis test. Pairwise comparisons between sarcoidosis and other DPLD or other DPLD and healthy controls showed no significant difference. n.s: nonsignificant (Kruskal-Wallis test).